Volume 27, Issue 1 pp. 152-158

ORIGINAL ARTICLE

Clinical parameters of therapeutic apheresis induction in clinically amyopathic dermatomyositis patients with rapid progressive interstitial lung disease

Maki Kagitani,

Corresponding Author

Maki Kagitani

[email protected]

orcid.org/0000-0001-7180-5517

Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan

Correspondence

Maki Kagitani, Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-cho, Takatsuki-shi 569-8686, Japan.

Email: [email protected]

Search for more papers by this author

Hayahito Nomi,

Hayahito Nomi

Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan

Search for more papers by this author

Haruhito Azuma,

Haruhito Azuma

Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan

Search for more papers by this author

Maki Kagitani,

Corresponding Author

Maki Kagitani

[email protected]

orcid.org/0000-0001-7180-5517

Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan

Correspondence

Maki Kagitani, Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-cho, Takatsuki-shi 569-8686, Japan.

Email: [email protected]

Search for more papers by this author

Hayahito Nomi,

Hayahito Nomi

Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan

Search for more papers by this author

Haruhito Azuma,

Haruhito Azuma

Blood Purification Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan

Search for more papers by this author

First published: 15 June 2022

https://doi.org/10.1111/1744-9987.13898

Citations: 2

Share a link

Email
Wechat
Bluesky

Abstract

Introduction

The purpose of this study is to clarify the clinical parameters of therapeutic apheresis (TA) induction in clinically amyopathic dermatomyositis patients with rapid progressive interstitial lung disease.

Methods

Literature publications prior to November 2021 from PubMed and Ichushi-Web were used. We collected details of TA and clinical features. The data were divided into two groups determined by the outcome, survived and deceased. Then, we estimated clinical parameters between them.

Results

There were 151 cases, 134 of which had reported outcomes and 64 of which were positive for the anti-MDA5 antibody. Eighty patients survived. Forty-eight patients were treated with plasma exchange and 34 with polymyxin-B immobilized fibers direct hemoperfusion. Regarding clinical parameters, only the PaO2 to FiO2 (P/F) ratio was useful. The cut-off point of the P/F ratio was 174 on the ROC curve.

Conclusion

The parameter for induction is considered when the P/F ratio is lower than 200.

CONFLICT OF INTEREST

The authors declare that there are no conflict of interest.

REFERENCES

1Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002; 46(4): 626–36.
10.1067/mjd.2002.120621
PubMed Web of Science® Google Scholar
2Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999; 26(7): 1527–33.
CAS PubMed Web of Science® Google Scholar
3Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010; 49(7): 1354–60.
10.1093/rheumatology/keq073
CAS PubMed Web of Science® Google Scholar
4Isoda K, Takeuchi T, Kotani T, Hata K, Shoda T, Ishida T, et al. Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/Subacufte interstitial pneumonia in dermatomyositis treated by cyclosporine a/Glucocorticosteroid combination therapy: a case control study. Plos One. 2014; 9(2):e89610.
10.1371/journal.pone.0089610
PubMed Web of Science® Google Scholar
5Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology. 2018; 57(7): 1212–21.
10.1093/rheumatology/key060
CAS PubMed Web of Science® Google Scholar
6Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012; 51(9): 1563–70.
10.1093/rheumatology/kes102
CAS PubMed Web of Science® Google Scholar
7Kotani T, Takeuchi T, Yoshimatsu Y, Ishida T, Yamamoto N, Fujiki Y, et al. Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute/subacute interstitial pneumonia in patients with dermatomyositis. Mod Rheumatol. 2016; 26(5): 738–43.
10.3109/14397595.2015.1134392
PubMed Web of Science® Google Scholar
8Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018; 28(1): 133–40.
10.1080/14397595.2017.1318468
CAS PubMed Web of Science® Google Scholar
9Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52(5): 1571–6.
10.1002/art.21023
CAS PubMed Web of Science® Google Scholar
10Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010; 49(3): 433–40.
10.1093/rheumatology/kep375
CAS PubMed Web of Science® Google Scholar
11Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010; 49(9): 1713–9.
10.1093/rheumatology/keq149
CAS PubMed Web of Science® Google Scholar
12Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012; 51(7): 1278–84.
10.1093/rheumatology/ker518
CAS PubMed Web of Science® Google Scholar
13Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005; 32(9): 1719–26.
CAS PubMed Web of Science® Google Scholar
14Silveira MG, Selva-O'Callaghan A, Ramos-Terrades N, Arredondo-Agudelo KV, Labrador-Horrillo M, Bravo-Masgoret C. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM: Int J Med. 2016; 109(1): 49–50.
10.1093/qjmed/hcv068
CAS Web of Science® Google Scholar
15Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000; 39(5): 428–30.
10.2169/internalmedicine.39.428
CAS PubMed Web of Science® Google Scholar
16Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016; 25(8): 925–33.
10.1177/0961203316651748
CAS PubMed Web of Science® Google Scholar
17Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Amashita HY, Kaneko H, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014; 24(4): 694–6.
10.3109/14397595.2013.874762
PubMed Web of Science® Google Scholar
18Watanabe A, Shiseki M, Oishi M, Kobayashi M, Oshima S, Osanai S, et al. Successful rituximab treatment in thrombotic thrombocytopenic purpura patients complicated by other autoimmune disorders: two case reports. Intern Med. 2021; 60(17): 2859–62.
10.2169/internalmedicine.6387-20
PubMed Web of Science® Google Scholar
19Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018; 57(12): 2114–9.
10.1093/rheumatology/key188
CAS PubMed Web of Science® Google Scholar
20Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology. 2014; 53(12): 2196–203.
10.1093/rheumatology/keu258
CAS PubMed Web of Science® Google Scholar
21Romero-Bueno F, del Campo PD, Trallero-Araguas E, Ruiz-Rodriguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020; 50(4): 776–90.
10.1016/j.semarthrit.2020.03.007
CAS PubMed Web of Science® Google Scholar
22Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology. 2012; 51(7): 1336–8.
10.1093/rheumatology/kes012
PubMed Web of Science® Google Scholar
23Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology. 2020; 59(11): 3284–92.
10.1093/rheumatology/keaa123
CAS PubMed Web of Science® Google Scholar
24Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020; 72(3): 488–98.
10.1002/art.41105
CAS PubMed Web of Science® Google Scholar
25Abe S, Azuma A, Mukae H, Ogura T, Taniguchi H, Bando M, et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012; 51(12): 1487–91.
10.2169/internalmedicine.51.6965
CAS PubMed Web of Science® Google Scholar
26Sasaki O, Dohi M, Harada H, Imamura M, Tsuchida Y, Yamaguchi K, et al. A case of Polymyxin b-immobilized fiber column treatment for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis. Case Rep Med. 2013; 2013: 1–5.
10.1155/2013/750275
Google Scholar
27Kagitani M. A successive case of acute progressive interstitial pneumonia of clinically amyopathic dermatomyositis with the anti MDA-5 antibody treated by polymyxin B-immobilized fibre column hemoperfusion therapy, plasma exchange and selective plasma exchange. Jpn J Apheresis. 2019; 38(3): 284–90.
Google Scholar
28Saito T, Mizobuchi M, Miwa Y, Sugiyama M, Mima Y, Iida A, et al. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clin Apher. 2021; 36(1): 196–205.
10.1002/jca.21833
PubMed Web of Science® Google Scholar
29Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome the Berlin definition. JAMA. 2012; 307(23): 2526–33.
PubMed Web of Science® Google Scholar
30 MA Williamson, LM Snyder, editors. Interpretation of diagnostic tests. 10th ed. Alphen aan den Rijn, Netherlands: Wolters Kluwer; 2015.
Google Scholar

Citing Literature

Volume27, Issue1

February 2023

Pages 152-158

Clinical parameters of therapeutic apheresis induction in clinically amyopathic dermatomyositis patients with rapid progressive interstitial lung disease

Abstract

Introduction

Methods

Results

Conclusion

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Clinical parameters of therapeutic apheresis induction in clinically amyopathic dermatomyositis patients with rapid progressive interstitial lung disease

Abstract

Introduction

Methods

Results

Conclusion

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Related

Information